Approximately half of all prostate cancers harbor a fusion that juxtaposes a TMPRSS2 transcriptional regulatory element, which is stimulated by potent androgens and the androgen receptor (AR), in front of an ERG oncogene6. This evidence concerns the gene AR and Familial prostate cancer.